Premium
Effect of lithium on plasma chlorpromazine levels
Author(s) -
Rivera-Calimlim Leonor,
Kerzner Boris,
Karch Fred E.
Publication year - 1978
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1978234451
Subject(s) - lithium (medication) , lithium carbonate , crossover study , chlorpromazine , chemistry , medicine , plasma concentration , blood pressure , endocrinology , plasma levels , anesthesia , placebo , ion , alternative medicine , organic chemistry , pathology , ionic bonding
The interaction of lithium and chlorpromazine (CPZ) was studied in healthy volunteers in a randomized crossover study. Each subject ingested two doses of CPZ (l00 mg) as the liquid concentrate: (1) without concurrent lithium therapy and (2) after a 7‐day treatment with lithium carbonate (900 mg/day). When CPZ was administered with lithium, peak plasma CPZ levels were 40.3% (mean) lower than those without lithium (p = 0.006), and the area under the CPZ plasma concentration time curve was 26.6% smaller (p = 0.08). The time to reach peak plasma CPZ levels was similar in both groups. All subjects slept for 4 to 6 hr after oral CPZ and had a maximum fall in both systolic (8 to 32 mg Hg) and diastolic (5 to 23 mg Hg) blood pressure at the time of peak plasma CPZ concentration. This lithium‐CPZ interaction may explain the low plasma CPZ levels reported previously in psychiatric patients taking both lithium and CPZ.